What is the primary reason for this 8-K filing?

This 8-K filing announces a planned executive leadership change in the finance department. Specifically, it details the retirement of the current CFO, Daniel J. Brennan, and the appointment of Jonathan Monson as his successor.

What are the terms of Daniel J. Brennan's retirement?

Mr. Brennan is retiring as CFO effective June 29, 2025, but will remain with the company as a senior advisor until October 3, 2025. He will continue to receive his current prorated base salary during this advisory period and is expected to enter into a Retirement Agreement for payments and benefits consistent with company plans.

What is Jonathan Monson's background and compensation package?

Mr. Monson, 51, has been with Boston Scientific since 1999 and has held key finance positions including Global Controller and Chief Accounting Officer. As the new CFO, his compensation includes a $700,000 base salary, an 80% incentive target, a $1.75 million promotional equity award vesting over four years, and participation in executive retirement and change-in-control plans.

Does this leadership change indicate any financial distress or operational issues?

The filing describes a planned retirement and internal promotion, with provisions for a smooth transition and continued advisory role for the outgoing CFO. There is no indication in the filing to suggest financial distress or operational issues; rather, it appears to be a standard executive succession.

BSX 8-K: Leadership Changes

Summary

Boston Scientific Corporation (BSX) announced a significant leadership transition in its finance department via an 8-K filing on April 23, 2025. Effective June 29, 2025, Executive Vice President and Chief Financial Officer Daniel J. Brennan will retire from his current role, transitioning to a senior advisor position until October 3, 2025. This planned retirement ensures a smooth handover and continued access to Mr. Brennan's expertise during the transition period. Concurrently, the company has promoted Jonathan Monson, currently Senior Vice President of Investor Relations, to succeed Mr. Brennan as Executive Vice President and Chief Financial Officer, effective June 30, 2025. Mr. Monson brings extensive experience within Boston Scientific, having previously served as Global Controller and Chief Accounting Officer, among other finance and accounting roles since 1999. His appointment signals an internal succession plan and leverages deep institutional knowledge in the critical CFO role.

Key Highlights

1Daniel J. Brennan, EVP and CFO, to retire effective June 29, 2025.
2Daniel J. Brennan will serve as a senior advisor from June 30, 2025, to October 3, 2025.
3Jonathan Monson, Senior Vice President of Investor Relations, appointed as the new EVP and CFO, effective June 30, 2025.
4Mr. Monson has a long tenure with Boston Scientific, starting in 1999, and has held significant finance roles including Global Controller and Chief Accounting Officer.
5Mr. Monson's compensation package includes a base salary of $700,000, bonus target of 80%, a significant promotional equity award of $1,750,000, and participation in executive retirement and change in control plans.
6The company has filed Mr. Monson's offer letter and a press release announcing these changes as exhibits.

BOSTON SCIENTIFIC CORP 8-K Report, Executive Changes (Apr 23, 2025)

Summary

Key Highlights

Frequently Asked Questions